$72.66
0.00% today
Nasdaq, Nov 27, 12:29 am CET
ISIN
US40637H1095
Symbol
HALO

Halozyme Therapeutics, Inc. Stock price

$72.66
+6.81 10.34% 1M
+18.12 33.22% 6M
+24.85 51.98% YTD
+24.87 52.04% 1Y
+16.19 28.67% 3Y
+31.52 76.62% 5Y
+55.01 311.67% 10Y
+70.82 3,848.91% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
-0.16 0.22%

New AI Insights on Halozyme Therapeutics, Inc. Insights AI Insights on Halozyme Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$8.5b
Enterprise Value
$9.4b
Net debt
$808.8m
Cash
$702.0m
Shares outstanding
117.5m
Valuation (TTM | estimate)
P/E
15.0 | 11.6
P/S
6.9 | 6.4
EV/Sales
7.5 | 7.0
EV/FCF
15.5
P/B
17.0
Financial Health
Equity Ratio
17.6%
Return on Equity
122.1%
ROCE
53.3%
ROIC
-
Debt/Equity
3.0
Financials (TTM | estimate)
Revenue
$1.2b | $1.3b
EBITDA
$808.5m | $893.6m
EBIT
$737.4m | $842.9m
Net Income
$595.5m | $738.0m
Free Cash Flow
$602.4m
Growth (TTM | estimate)
Revenue
31.2% | 32.5%
EBITDA
47.5% | 43.6%
EBIT
54.6% | 52.8%
Net Income
51.7% | 66.2%
Free Cash Flow
53.4%
Margin (TTM | estimate)
Gross
84.6%
EBITDA
65.1% | 66.4%
EBIT
59.3%
Net
47.9% | 54.9%
Free Cash Flow
48.5%
More
EPS
$4.9
FCF per Share
$5.1
Short interest
13.4%
Employees
350
Rev per Employee
$2.9m
Show more

Is Halozyme Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Halozyme Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Halozyme Therapeutics, Inc. forecast:

11x Buy
69%
5x Hold
31%

Analyst Opinions

16 Analysts have issued a Halozyme Therapeutics, Inc. forecast:

Buy
69%
Hold
31%

Financial data from Halozyme Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,243 1,243
31% 31%
100%
- Direct Costs 192 192
13% 13%
15%
1,051 1,051
35% 35%
85%
- Selling and Administrative Expenses 172 172
15% 15%
14%
- Research and Development Expense 70 70
12% 12%
6%
808 808
48% 48%
65%
- Depreciation and Amortization 71 71
0% 0%
6%
EBIT (Operating Income) EBIT 737 737
55% 55%
59%
Net Profit 595 595
52% 52%
48%

In millions USD.

Don't miss a Thing! We will send you all news about Halozyme Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Halozyme Therapeutics, Inc. Stock News

Neutral
PRNewsWire
2 days ago
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference. The presentation is scheduled for Tuesday, December 2 at 10:20am PT / 1:20pm ET.
Positive
Investors Business Daily
6 days ago
The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter.
Neutral
PRNewsWire
9 days ago
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year ...
More Halozyme Therapeutics, Inc. News

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Head office United States
CEO Helen Torley
Employees 350
Founded 1998
Website www.halozyme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today